-
07:11:37 PM

AUPH Stock News

01/24/23 4:00 PM
Nasdaq : AUPH
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
Aurinia’ s newly allowed U.S. Patent Application reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS. The newly allowed application provides patent coverage that supplements Aurinia’ s existing U.S. Patent No. 10,286,036, which is listed in the Orange Book and claims an FDA- approved method of using LUPKYNIS.
RHEA-AI
very positive
01/04/23 4:05 PM
Nasdaq : AUPH
conferences
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
Aurinia Pharmaceuticals Inc. today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11 th at 4:30 p.m. Pacific Time/ 7:30 p.m. Eastern Time in San Francisco, CA.. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company...
RHEA-AI
neutral
01/03/23 9:12 AM
Nasdaq : AUPH
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
Aurinia Pharmaceuticals Inc. announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review directed at Aurinia’ s U.S. Patent No. 10,286,036,...
RHEA-AI
negative
11/30/22 4:05 PM
Nasdaq : AUPH
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc., a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the U.K. Medicines and Healthcare products Regulatory Agency has granted the Great Britain marketing authorization of LUPKYNIS ® to treat adults with active lupus nephritis, a serious...
RHEA-AI
very positive
10/28/22 5:30 PM
Nasdaq : AUPH
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
Aurinia Pharmaceuticals Inc. today announced that it will release financial and operational results for third quarter 2022 on Thursday, November 3, 2022, before markets open. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted...
RHEA-AI
neutral
10/27/22 12:00 PM
Nasdaq : AUPH
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
Aurinia Pharmaceuticals Inc., a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from multiple studies of LUPKYNIS ® will be presented at the American Society of Nephrology Kidney Week 2022, taking place November 3-6 in Orlando, Florida. Title: Enlight-LN: A...
RHEA-AI
neutral